DSIP
Nonapeptide originally isolated from sleeping rabbit blood in 1977; studied for slow-wave sleep induction and EEG delta-wave modulation. Improves sleep architecture without sedation or dependence. Very limited US availability — custom synthesis required.
What Research Shows
Studied for delta-wave (slow-wave) sleep promotion via opioid and GABA-B receptor modulation, and cortisol/CRH suppression. Studies measure EEG delta power (0.5–4 Hz), NREM sleep duration, and sleep onset latency in polysomnography models. Landmark 1977 discovery paper; human trial data limited and inconsistent.
Pros & Cons
- +DSIP improves sleep architecture (specifically slow-wave sleep) rather than simply increasing total sedation
- +No respiratory depression — critical safety advantage over conventional sleep medications
- +Selank shows no withdrawal or dependence effects in published rodent studies — unlike benzodiazepines
- +Selank is intranasal — no injections required
- +Cortisol-reducing effect of Selank may have positive downstream effects beyond sleep
- +Non-addictive mechanism — neither compound acts on GABA-A receptors the way benzodiazepines do
- −DSIP has an extremely short plasma half-life (~30 minutes) — the compound degrades quickly, making dosing protocols challenging
- −DSIP is practically unavailable from SEA vendors as of 2026 — specialised custom synthesis required
- −Human clinical data for DSIP is very limited and inconsistent across published studies
- −Selank's sleep benefits are a secondary effect of its anxiolytic action — it is not a direct sleep-inducing agent
- −Effects of DSIP in human volunteers have shown high inter-individual variability in the few published trials
- −Without access to sleep EEG monitoring, it is difficult to verify sleep architecture improvement objectively
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary significantly.
DSIP-induced delta sleep changes are measurable within the first sleep cycle in animal polysomnography studies. Selank's anxiolytic effects are measurable within 30–60 minutes in animal models and may require 3–7 days of consistent use for stable baseline improvement in self-researchers.
What People Research This For
Practical Questions
What time of day should I use Selank for sleep benefits?
For sleep applications, self-researchers typically use Selank 60–90 minutes before bedtime. This timing allows the anxiolytic effect to develop before sleep onset, helping reduce the hyperarousal and racing thoughts that prevent falling asleep. Morning use is more common when the goal is daytime anxiety reduction — the compound can be used at either time.
Can DSIP actually be sourced for research?
DSIP is not stocked by most SEA research peptide vendors due to low demand and synthesis complexity. Researchers requiring DSIP typically contact specialised custom peptide synthesis laboratories directly. The short half-life also means freshly synthesised material is preferable. This category is included because the research literature is extensive, but practical sourcing is significantly harder than for BPC-157 or Selank.
Where to Buy DSIP in Southeast Asia
DSIP has limited SEA-accessible vendor availability as of March 2026. Most SEA-accessible vendors do not stock this compound routinely.
Contact vendors directly to check current stock, or see our full SEA vendor comparison for contact details.